Clifton Baker, MD
General Practice · Denton, NCNPI 1053370098
Payments from drug & device makers
Across 320 payments — averaging $15.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$766
- Novo Nordisk$655
- Lilly USA, LLC$622
- AbbVie$349
- Kowa Pharmaceuticals America, Inc.$268
- Exact Sciences$255
- plus $2K from 35 others
What the payments were for
- Food & beverage$5,094100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 41 | $766 |
| Novo Nordisk | 46 | $655 |
| Lilly USA, LLC | 40 | $622 |
| AbbVie | 22 | $349 |
| Kowa Pharmaceuticals America, Inc. | 21 | $268 |
| Exact Sciences | 12 | $255 |
| GSK | 16 | $244 |
| Merck | 11 | $179 |
| Astellas Pharma US Inc | 12 | $179 |
| Amarin Pharma, Inc. | 13 | $169 |
| Boehringer Ingelheim | 10 | $159 |
| Novartis | 10 | $144 |
| Bayer | 8 | $131 |
| Pfizer | 5 | $91 |
| Biohaven Pharmaceuticals, Inc. | 6 | $86 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $60 |
| E.r. Squibb & Sons, L.L.C. | 3 | $59 |
| Lundbeck LLC | 4 | $58 |
| Amgen | 3 | $58 |
| Shield Therapeutics Inc | 3 | $52 |
| Mylan Specialty L.p. | 3 | $43 |
| Verona Pharma, Inc. | 2 | $41 |
| Abbott | 2 | $37 |
| Johnson & Johnson | 3 | $34 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $34 |
| Eisai Inc. | 2 | $27 |
| Inspire Medical Systems, Inc. | 1 | $27 |
| Neurocrine Biosciences, Inc. | 1 | $25 |
| Sanofi-aventis U.S. LLC | 1 | $25 |
| Medtronic | 1 | $25 |
| Genentech USA, Inc. | 2 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| Scpharmaceuticals Inc. | 1 | $21 |
| Vertex | 1 | $18 |
| Vanda Pharmaceuticals Inc. | 1 | $18 |
| OWP Pharmaceuticals, Inc. | 1 | $16 |
| Kyowa Kirin, Inc. | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| Phadia US Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $12 |
| Axsome Therapeutics, Inc. | 1 | $12 |
How this compares
$5,094 in reported general payments places this provider in the 95th percentile of 2,924 general practice providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 466 | $298,202 |
| EliquisApixaban | 357 | $229,753 |
| JardianceEmpagliflozin | 198 | $169,725 |
| OzempicSemaglutide | 141 | $151,828 |
| XareltoRivaroxaban | 117 | $74,540 |
| EntrestoSacubitril/Valsartan | 99 | $72,886 |
| MounjaroTirzepatide | 49 | $50,558 |
| TrulicityDulaglutide | 40 | $46,203 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 42 | $37,048 |
| RybelsusSemaglutide | 17 | $25,635 |
| Tresiba Flextouch U-200Insulin Degludec | 24 | $15,574 |
| JanuviaSitagliptin Phosphate | 19 | $14,839 |
| MyrbetriqMirabegron | 25 | $13,898 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 33 | $11,055 |
| LinzessLinaclotide | 18 | $10,157 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Symbicort | $766 | $301,854480 claims |
| PfizerEliquis, Abrysvo | $91 | $240,807390 claims |
| Novo NordiskOzempic, Rybelsus | $655 | $177,464158 claims |
| Boehringer IngelheimJardiance | $159 | $169,725198 claims |
| Lilly USA, LLCMounjaro, Trulicity | $622 | $96,76089 claims |
| Johnson & JohnsonXarelto | $34 | $74,540117 claims |
| NovartisEntresto | $144 | $72,88699 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $244 | $43,75859 claims |
| MerckJanuvia | $179 | $14,83919 claims |
| Astellas Pharma US IncMyrbetriq | $179 | $13,89825 claims |
| AbbVieLinzess | $349 | $10,15718 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,924 general practice providers in North Carolina.
Other general practice in Denton
- Matthew MillerCharlotte$937K
- James BarberDurham$768K
- Robert LoweCharlotte$615K
- Howard JamesSanford$483K
- Clifton CameronFayetteville$404K
- Michael HarrisonRaleigh$249K
- Ronnie DavidsonMooresville$151K
- Leo HaydtHolly Springs$119K
- Andrew KellyGreensboro$115K
- Mark HymanGreensboro$95K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.